The Department of Health of Puerto Rico has granted authorization to market Endari, an oral powder treatment for sickle cell disease (SCD). The first FDA-backed oral glutamine, Endari has been approved for use in the US, Israel, UAE, Kuwait, Qatar, Bahrain, and Oman, and can be prescribed to patients aged five and older to help greatly lower pain crisis frequencies, hospitalizations, and other complications.

As an organization focused on combating SCD, the OxyDial team is thrilled to see continued progress on improving quality of life and care for SCD patients worldwide.

Click here to read details: https://lnkd.in/e2cKbTU7

#EmmausLifeSciences #EndariApproval #SickleCellDisease #SickleCellAnemia #SickleCellTreatment #HealthInnovation #PuertoRicoHealthcare #SCDTreatment #FDAApproved #GlobalHealthcare #Endari #ResearchConnectivity #ImprovingPatientOutcomes #MedicalProgress #GlobalSCDCare #HealthTech #PatientCareInnovation #GlutamineTreatment #EndariInPuertoRico